Pharmaceutical Technology's Equipment and Machinery Trends Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Equipment and Machinery Trends Survey
The pharmaceutical industry plans moderate increases in spending for equipment and machinery in 2008. Investments include equipment for solid-dosage manufacturing, active pharmaceutical ingredients, and parenteral manufacturing.


Pharmaceutical Technology
Volume 3, Issue 32

Capital expenditures, specifically spending on machinery and equipment, are one barometer of the health of the pharmaceutical manufacturing sector. To examine the state of this segment, Pharmaceutical Technology conducted a survey of its readers to evaluate spending levels, spending on equipment type, factors influencing spending, and regional spending habits.

For the purposes of the survey, machinery and equipment refers to machinery and equipment for solid-dosage, aseptic, sterile, parenteral, and active pharmaceutical ingredient (API) manufacturing, quality control and assurance (including analytical instrumentation and laboratory equipment), process control and automation, pharmaceutical packaging, and environmental control.


Respondents profile
The survey (see sidebar, "Respondents' profile") was targeted at individuals who operate, work with, process products through, supervise, suggest, purchase, or review expenditures for pharmaceutical machinery and equipment.

Spending levels in 2007


Figure 1.
The results of the survey showed that nearly half (47.4%) of respondents increased spending on machinery and equipment over spending levels in 2006 (see Figure 1). Almost a quarter (21.2%) said spending stayed the same, and 14.3% of respondents said spending at their companies decreased compared with 2006 levels.

Spending increases were most prevalent among respondents from consumer healthcare companies (81.8% of these companies increased spending), followed by generic-drug companies (61.5%), analytical services companies (60.0%), contract manufacturers (53.1%), and innovator pharmaceutical companies (41.8%).

The survey also asked how much companies spent on machinery and equipment as both a percentage of sales and an absolute level. The mean percentage of overall sales spent on equipment and machinery in 2007 was 5.3%; the median was 2.1–4%.


Figure 2.
Almost one-third (29.9%) spent less than 2% of their sales on machinery and equipment in 2007, 21.2% between 2.1–4%, and 18.2% between 4.1–6% (see Figure 2). Surprisingly, roughly 20% spent more than 8% of their sales on equipment and machinery in 2007.

The mean expenditure on machinery and equipment in 2007 was $59.6 million. The median expenditure was $1–10 million.

Spending trends in 2007

The survey asked companies that increased spending in 2007 whether the percentage increases were greater than in previous years and what type of equipment they purchased.

For those companies that spent more in 2007 than in 2006, 66% said the percentage increase was greater than their 2005–2006 increase, 28% said it was on par, and 2% said it was less.

Generic-drug companies and analytical services companies were the most likely to have increased spending by a greater percentage in 2007 compared with 2006. The survey showed that 83.3% of the respondents from generic-drug companies and 83.3% from analytical service companies said that their percentage increase in spending was greater in 2007 than in 2006. Only 12.5% of generic-drug companies, and 16.7% of analytical service companies said that spending in 2007 was on par with 2006.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here